TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of social ties elicited by the composite name generator
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Presence of HCV Core protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Presence of HCV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Presence of SPP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in overall KCCQ scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in clinical summary KCCQ scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in physical domain KCCQ scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Gait Deviation Index (GDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angiographic patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline of Percentage of Perfusion Vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Necrotic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of local re-growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of macroscopically positive resection margin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Transplant rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-Term Outcomes of ProChondrix CR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline of renal function markers (GFR and creatinine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area Under the Curve Extrapolated to Infinity (AUC0-∞) of Plasma LY2886721
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Plasma LY2886721
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cnadir of Plasma Amyloid β (Aβ)1-40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient State Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electromyography (Frontal EMG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Nasal Obstructive Symptom Evaluation (NOSE) Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Best corrected visual acuity at intermediate distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum tolerated dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Selection of first-line therapy option
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Apoptosis Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of initiation and termination of each fluid bolus administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of each fluid bolus administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking Dependence Among Smokers as Measured by Fagerstrom Test of Nicotine Dependence (FTND) Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Self-reported Smoking Abstinence and Point Prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Incidence of Postoperative Complications (PCs) and Postoperative Pulmonary Complications (PPCs)
Endpoint domain: Adverse events/effects
Primary endpoint: All Adverse Events (Lab Toxicities Reported Were Only Grade 3 and Higher)
Endpoint domain: Adverse events/effects
Primary endpoint: Skeletal effects of aromatase inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Quality of life of the donor
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: incidence of postpartum infectious morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in hearing response at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of other NF2 related tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 30% improvement of JIA activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of systemic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical integration
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Psychological integration
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients with IGDT-10 score above 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vessel Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of transthyretin (TTR) amyloidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac progression of transthyretin (TTR) amyloidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Early Bactericidal Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants Free of Chronic Treatment Failure (CTF) Through 36 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Experiencing Cryoablation Procedure Events (CPEs) Through 12 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Measurable change in post-treatment tumor biology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Grades II-IV Acute GVHD-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in Electroencephalogram amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Electroencephalogram Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Stress using state trait anxiety inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Performance of the CPAI Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in visual analog pain score (vaginal area)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cervical range of motion (CROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myofascial Diagnostic Scale (MDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Elbasvir (EBR)/Grazoprevir (GZR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pelvic floor muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 hour Ambulatory Blood Pressure monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain free maximum walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain free maximum walking time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of the protocol
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity of automated total body digital photography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score on visual analogic scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of trials correct
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vancomycin-associated acute kidney injury (VAN-AKI) occurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pubertal stage assessed by Tanner score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FSH (Follicle Stimulating Hormone) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: GAD
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Thyroid Eye Disease Clinical Activity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of severe treatment-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of medical-device related adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in inflammation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Total Corneal Fluorescein Staining Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Dryness Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in heart rate during the speed-endurance production training (SEPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in repeated sprint ability (RSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in countermovement jump (jump height in centimeters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day CO-verified Tobacco Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fusion/Union
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adherence Rates
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Control of GH and IGF-I excess
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: First Complete Closure of the EB Target Wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Primary Performance Patient Assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants Who Were Non-Failures
Endpoint domain: Adverse events/effects
Primary endpoint: CT-derived computed fractional flow reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tactile Hypersensitivity Scores Immediately After Topical Dentifrice Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Air Blast Hypersensitivity Scores Immediately After Topical Dentifrice Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Tactile Hypersensitivity Score After 3 Days of Dentifrice Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Air Blast Hypersensitivity Score 3 Days After Dentifrice Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety of repeated IV immunizations
Endpoint domain: Adverse events/effects
Primary endpoint: brain activity and connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Abdominal and axillary skin surface temperatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the number of manic switches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the number of depressive episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Early Morning UPDRS Part III Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in Parkinson's Disease Sleep Scale (PDSS)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in the number of IOP lowering medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of acute urine retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of full stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Inherited gene mutations susceptible to epithelial ovarian cancer
Endpoint domain: Mortality/survival
Primary endpoint: Diastolic cardiac function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Muscle strength of the upper limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: muscle strength of the lower limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Tear Protein and/or Cytokine Composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evolution of oral health status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Toxicity of Bevacizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in TTR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonoscopy non-adherence rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean relative error of blood glucose readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation with glucose hexokinase based assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clark error grid evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of 24 hour smoking abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stimulated C-peptide response levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 24-hr urine protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: adverse events including hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Knee Injury and Osteoarthritis Outcome Score (KOOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Participants Responding to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scarred areas comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Postoperative Pain Levels on Postoperative Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antiemetic Consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in microcirculatory blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in muscle fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Severe transplant-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Stable donor engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subclinical inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Score on Decisional Conflict Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Score on COMRADE Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of stent struts uncovered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Extent of chronic graft versus host disease (GVHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ease of Deflation of the Titan® OTR Pump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total and Regional Brain Compartmental Kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Responsive feeding
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Psychiatric Drugs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pathologic complete response rate (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of incidence of death
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients with hernia free survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of genomic alteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of fentanyl citrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of COPD exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Osteoprotegerin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of 17-item Hamilton Depression Scale (HAMD-17) From Baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Barthel Index (BI) From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of Hamstrings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: SLR test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Knee Extension test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Area Under the Free Plasma Concentration Time Curve From Zero to 24 Hours (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unbound Area Under the Free Plasma Concentration Time Curve From Zero to 24 Hours (AUC0-24u)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unbound Maximum Observed Plasma Concentration (Cmaxu)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in ANS modulation directed to the heart and vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in baroreflex control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number and type of serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients withdrawing levocetirizine treatment due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Plasma HIV-1 RNA <50 c/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with clinical improvement of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 15-Prostaglandin dehydrogenase expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of dAd5GNE vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in the total score of the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of non-fatal infarction or death
Endpoint domain: Mortality/survival
Primary endpoint: INTEM parameters change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EXTEM parameters change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FIBTEM parameters change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV Vaccine Response Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of lower limb amputations
Endpoint domain: Mortality/survival
Primary endpoint: Change in hip flexion-extension range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: effectiveness of blood fix treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of blood fix treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Brown/beige fat tissue distribution and activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subcutaneous glucose evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in average number of flares
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase II dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of MRI-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Cytokine Total Mass in Pleural Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in Change of Cytokine Concentrations in Pleural Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maternal retention in care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention